Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Search Seller Projects – , Healthcare
Asia: Japan
Japanese hospital specialized in cancer treatment seeks investment.
The Japanese hospital is specialized in integrated and advanced treatment of cancer, comprising examination, prevention, and treatment. It has a close cooperative relationship with various advanced research institutions and medical institutions. It has been continuously studying projects such as advanced treatment of cancer, ultra-early detection, and recurrence prevention for a long time. The company now seeks investment.
Asia: South Korea
Medical company located in the Republic of Korea seeks investment
South Korean medical device production and sales company was founded in 2001 and now has 13 employees. Many of the company's products have independent intellectual property rights in China, Japan, South Korea, Russia, the United States, Australia, Europe and other parts of the world. Its excreta collection equipment launched by the company helps to maintain personal hygiene and effectively reduce and prevent the occurrence of bedsore. The product is composed of a portable host and a disposable collection part. It has the following advantages: excellent design and advanced technology (prevent secondary bacterial infection and pollution, easy to handle waste and observe bloody excreta, environment-friendly, less waste, less cost, easy to use, excellent adhesion). The simple cleaning bag products have passed the test. The company is now looking for investment.
Asia: Japan
Japanese pelvic correction company seeks 100% acquisition.
Japanese company was founded in the 2000s, located in Tokyo. It is mainly engaged in the operation of pelvic correction and yoga training services. Its main customers are high-income individuals aged 30 to 40. The company has 350 stores (including franchisees) worldwide, of which 86% are in Japan. The company's revenue in 2019 was 11.5 billion JPY and its EBITDA was 1.3 billion JPY. At present, the company wants to sell its business, and the acquisition price will not be less than 15 billion JPY.
Asia: Hong Kong
Medical and surgical robot company in Hong Kong seek $30 million for financing
The company is an international medical and surgical R&D robot start-up in Hong Kong, which is led by a strong management team, including 30 year-experienced personnel and other professionals in this field. The market scale of this field is expected to reach US $20 billion and a compound annual growth rate of more than 10% though 2020. Its product has many intellectual property rights, including a magnetic anchor robot system, robot manipulator, etc. The company is now focusing on the development of two revolutionary non-invasive robot systems and seeking $30 million in financing. The first is a disposable soft robot colonoscopy system for colorectal cancer diagnosis which has completed the animal clinical trials and human clinical trials are planned to be conducted in 2020 S2 and are expected to be put into commercial production in 2021. Another is a surgical robot system for colorectal, urological, and gynecological surgery. This robot system is the first in the market to provide forward and reverse surgery, it expands the application field of robot surgery to most abdominal and pelvic surgery processes. The product is now in the preparation stage of clinical trial and is expected to be put into commercial production before 2023.
Asia: Japan
Japanese nursing Robot company seeks investment.
Japanese-based nursing robot company has an excretion treatment device for a wide range of patients (elderly, disabled, recovery, etc.). The device is simple to use and designed with a small size. A high automation level makes the monitoring system more reliable.
Europe: Israel
Israeli Bladder Cancer Treatment Company Seeks to Sell 100% Equity
The Israeli company has developed and commercialized a device for the treatment of Non-muscle Invasive Bladder Cancer (NMIBC). The company’s device has a CE mark and is currently considered by the European Association of Urology (EAU) and the National Institute for Health and Care Excellence (NICE) as one of only few reliable and effective treatments for NMIBC. The company has performed 40,000 treatments in the past 20 years in Europe (incl. UK), Turkey and Israel. The founder and inventor seek to sell the company to concentrate on R&D.
The software-controlled device is minimally invasive and enables disease-free survival following the therapy while maintaining higher bladder preservation rates.
Current annual sales are USD 1 million. Since it is a one-product company, fixed costs remain relatively high (space, accounting, insurance, regulatory). Integration of the product into a large-scale operation is expected to realize cost synergies within the first year of operation.
Europe: Germany
Mass Hands Sanitizer
A machine for hand-sanitizing to be located in public areas (e.g. airports, schools) and events (e.g. fairs, stadiums, etc.) in order to contain and prevent COVID-19 while minimizing waste from empty disinfectant bottles and avoiding the need to recycle them.
Europe: Germany
German autoimmune disease IVD company seeks investment.
The company mainly develops and produces autoimmune disease diagnostic reagent products for early detection, diagnosis and prediction of autoimmune diseases. At present, the company has introduced more than 150 products in the field of diagnostic reagents. Main diagnostics include rheumatology, thrombosis, gastroenterology, vasculitis, thyroid, diabetes, liver disease and lyme disease ELISA detection, immunofluorescence based on cell and tissue slides, and IFA. With more than 200 employees in 20 countries and sales in more than 90 countries.
Europe: Germany
German biological IVD company seeks investment.
The company was founded in Germany and is mainly engaged in the R&D and production of high-end diagnostic system solutions. At present, the global market has covered more than 100 countries and more than 90 kinds of clinical chemical and reaction reagents. The company's revenue in fiscal year 18 / 19 exceeded 60 million euros, of which 80% came from reaction reagents and 20% from testing instruments.
At present, the company has more than 500 employees and more than 200 employees in its headquarters in Germany. The company has R&D institutions in Germany, France, India and China.
At present, the company has more than 500 employees and more than 200 employees in its headquarters in Germany. The company has R&D institutions in Germany, France, India and China.
Europe: Germany
German biomedicine company seeks investment.
The company is a chip laboratory for virus microbial detection, focusing on the timely diagnosis equipment of single molecule sensitivity. Its advantages are
1 single molecule sensitivity: direct single molecule counting without nucleic acid extraction or PCR amplification
2 data analysis network security: safe and convenient desensitization data sharing, convenient for users to build a real-time infectious disease monitoring network
3. Covering large range in single test: up to 120 kinds of viral microorganisms can be detected in a single test, covering almost all viruses, bacteria and parasites endangering human health
4. 15 minutes from the sample to the result: it can respond quickly to the epidemic and formulate treatment and isolation plans
5. Low cost (8 yuan / time / microorganism)
The company has a patented technology, which is the industry's only multi fluorescent labeling coding technology, can detect all dangerous viruses and microorganisms in the human body and make immediate diagnosis at the bedside. It is 40 times cheaper and 20 times faster than the existing scheme. It is predicted that it will occupy 6.3-10.5 billion in infectious disease diagnosis. The company is currently the only molecular diagnostic company that can balance high flux, fast, low cost and accuracy. The company is also a an all-platform company, earning revenue from equipment, consumables, customized development fees and third-party licensing fees. The company is a global innovation company, R&D in Germany and made in China.
1 single molecule sensitivity: direct single molecule counting without nucleic acid extraction or PCR amplification
2 data analysis network security: safe and convenient desensitization data sharing, convenient for users to build a real-time infectious disease monitoring network
3. Covering large range in single test: up to 120 kinds of viral microorganisms can be detected in a single test, covering almost all viruses, bacteria and parasites endangering human health
4. 15 minutes from the sample to the result: it can respond quickly to the epidemic and formulate treatment and isolation plans
5. Low cost (8 yuan / time / microorganism)
The company has a patented technology, which is the industry's only multi fluorescent labeling coding technology, can detect all dangerous viruses and microorganisms in the human body and make immediate diagnosis at the bedside. It is 40 times cheaper and 20 times faster than the existing scheme. It is predicted that it will occupy 6.3-10.5 billion in infectious disease diagnosis. The company is currently the only molecular diagnostic company that can balance high flux, fast, low cost and accuracy. The company is also a an all-platform company, earning revenue from equipment, consumables, customized development fees and third-party licensing fees. The company is a global innovation company, R&D in Germany and made in China.
Europe: Britain
British medical equipment company seeks for investment.
The company is developing a pump that can be implanted directly into the failing heart to treat advanced chronic heart failure. The company aims to apply novel technologies and designs to produce ventricular assist devices (VADs) with obvious advantages over existing methods, including less invasive surgery, reduced thrombosis and control systems optimized for quality of life. The company is raising £ 7.5 million and is now steadily realizing the first implantation of the company's products in the human body in 2021.
Europe: Britain
British clinical biotechnology company seeks for acquisition.
The company is a UK based clinical biotechnology company dedicated to the development of new anti-infectives. Founded in the UK in 1997, it was listed on the London Stock Exchange (LSE) sub market alternative investment market (AIM) in 2017, with a market value of £ 19 million. In 2018, the first new drug for research (IND) was successfully launched in the United States, has obtained fast track qualification, and is starting the planned clinical plan. The pilot drug code named XF-XX has completed a clinical trial funded by the U.S. government. Different from traditional antibiotics, XF-XX shows excellent resistance to a specified bacterial in the laboratory - producing a series of potential low bacterial resistance, which can be used to prevent and treat methicillin resistant Staphylococcus aureus (MRSA) infection. Compared with traditional antibiotics, XF platform has the advantages of killing bacteria quickly, killing bacteria in any growth period and killing bacteria in staphylococcal bacterial biofilm. It is active against all Gram-positive bacteria tested so far and selected Gram-negative bacteria. No bacterial (MRSA) resistance was found. The company continued to strengthen its patent rights and granted XF biofilm patents in Canada in 2018, bringing the total number of patents granted by XF platform to 95.
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact Us